Compare AbbVie Inc (ABBV) vs Amplify Cybersecurity ETF (HACK) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

HACK trades at $110.27, up 3.08% with strong bullish momentum from moving averages but overbought RSI signals. The cybersecurity ETF benefits from growing sector spending exceeding $300 billion in 2026, with recent partnerships expanding market reach. Technical indicators show strong trend strength while oscillators suggest potential near-term consolidation.

The outlook remains positive given cybersecurity's essential role in AI adoption, though elevated RSI levels indicate near-term overbought conditions. Key risks include sector competition and market volatility, while institutional momentum supports continued growth potential in the expanding cybersecurity market.